Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted therapy with fludarabine and alemtuzumab in young CLL patients
NCT00462332Phase 2Completed
- Sponsor
- GIMEMA
- Start
- May 2007
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by GIMEMA. Started May 2007; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00462332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462332.